Showing 101–125 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Wilson L, Gracie L, Kidy F, Thomas GN, Nirantharakumar K, et al.
…rring in low- and middle-income countries (LMICs). The only vaccine licenced for the prevention of TB has limited protection for adolescents, adults and vulnerable populations. A safe and effective vaccine for all populations at risk is imperative to achieve global elimination of…
Kulesza J, Kulesza E, Koziński P, Karpik W, Broncel M, et al.
Despite controversy over the protective effect of the BCG (Bacille Calmette-Guérin) vaccine in preventing pulmonary tuberculosis (TB) in adults, it has been used worldwide since 1921. Although the first reports in the 1930s had noted a remarkable decrease in child mortality after…
Foster M, Hill PC, Setiabudiawan TP, Koeken VACM, Alisjahbana B, et al.
The tuberculosis (TB) vaccine Bacillus Calmette-Guérin (BCG) was introduced 100 years ago, but as it provides insufficient protection against TB disease, especially in adults, new vaccines are being developed and evaluated. The discovery that BCG protects humans from becoming inf…
Penny M. Heaton, Jeffrey S. Barrett
…scribes some of the institute's work on candidate drugs and vaccines against tuberculosis, the leading infectious diseases killer in the world. The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a nonprofit biotechnology organization focused on diseases that dispr…
Maeyama JI, Iho S, Suzuki F, Hayashi D, Yamamoto T, et al.
…is involves taking advantage of Bacillus Calmette-Guérin's (BCG) superior effects on childhood tuberculosis. Accordingly, here we aimed to develop a booster vaccine for adults who received the BCG vaccine during early childhood. Therefore, we first devised a system to assess the …
Nadhila Idris, Muhammad Nasrum Massi, Rizalinda Sjahril, Ahyar Ahmad, Mochammad M Hatta, et al.
…h despite the availability of Bacille Calmette-Guérin (BCG) vaccination. The limited efficacy of BCG in adults and the low sensitivity of conventional diagnostic methods highlight the urgent need for novel antigens to improve TB immunodiagnostics. **METHODS:** This study co…
Ratih Pujilestari, Andriansjah Rukmana, Anis Karuniawati, M Usman, S Ismail, et al.
… Mycobacterium tuberculosis (Mtb). Bacille Calmette-Guérin (BCG) is the only licensed vaccine against TB, and it is effective in children but not in adults. The Vaccine Research Team, Department of Microbiology FKUI has developed a DNA-based TB vaccine candidate pcDNA3.1-rpfB. Th…
Ko A, Wui SR, Ryu JI, Lee YJ, Hien DTT, et al.
…d by Mycobacterium tuberculosis . Bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently available, but it is not sufficiently effective in preventing active pulmonary TB or adult infection. With the purpose of developing an improved vaccine against TB that can o…
D'Auria G, Hodzhev Y, Aceves-Sánchez MJ, Moya A, Panaiotov S, et al.
Background Bacillus Calmette-Guérin (BCG) remains the only vaccine to prevent tuberculosis (TB) during childhood, with relatively low to no efficacy against pulmonary TB in adolescents and adults. BCG consists of close to 15 different substrains, where genetic variations among th…
Dellagostin OA, Borsuk S, Oliveira TL, Seixas FK
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG va…
Paloma Rezende Corrêa, Marcos Gustavo Araujo Schwarz, Meydson Benjamim Carvalho Corrêa, Márcia Berrêdo-Pinho, Leila Mendonça-Lima
**BACKGROUND:** The Bacille Calmette-Guérin (BCG) vaccine, developed in the early 20th century, remains the only widely approved prophylactic against tuberculosis (TB). It was derived from an attenuated strain of Mycobacterium bovis. Its protective efficacy against pulmonary…
Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, et al.
…sis Relevant immune targets of the partially efficacious TB vaccine bacille Calmette-Guérin (BCG) remain poorly defined. Mucosal-associated invariant T (MAIT) cells are MHC-related protein 1 (MR1)-restricted T cells, which are reactive against M. tuberculosis , and underexplored …
Jauro S, Larson EC, Gleim JL, Wahlberg BM, Rodgers MA, et al.
…tcomes in people living with HIV. Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, is effective in infants, but its efficacy in adolescents and adults is limited. In this study, we investigated the immune responses elicited by BCG administered via i.v. or intradermal…
Yu J, Fan X, Luan X, Wang R, Cao B, et al.
…seriously affects human health. Until now, the only anti-TB vaccine approved for use is the live attenuated Mycobacterium bovis (M. bovis) vaccine - BCG vaccine, but its protective efficacy is relatively low and does not provide satisfactory protection against TB in adults. There…
Ahmed A, Rakshit S, Adiga V, Dias M, Dwarkanath P, et al.
BCG turns 100 this year and while it might not be the perfect vaccine, it has certainly contributed significantly towards eradication and prevention of spread of tuberculosis (TB). The search for newer and better vaccines for TB is an ongoing endeavor and latest results from tria…
Xiaofang Zhao, Caihong Guo, Lianwen Wang, Zhijun Liu
…merge in the absence of systematic interventions. While the BCG vaccine provides substantial protection against infantile TB, its efficacy against pulmonary TB in adults varies significantly. Currently, six candidate vaccines aimed at preventing or delaying the progression from L…
Valencia-Hernandez AM, Zhao G, Miranda-Hernandez S, Segura-Cerda CA, Pedroza-Roldan C, et al.
Bacille Calmette-Guérin (BCG) remains the only licensed vaccine against tuberculosis (TB). While BCG protects against TB in children, its protection against pulmonary TB in adults is suboptimal, and the development of a better TB vaccine is a global health priority. Previously, w…
Solomon Jauro, Erica C. Larson, Janelle L. Gleim, Brendon M. Wahlberg, Mark A. Rodgers, et al.
…in people living with HIV (PLWH). Bacillus Calmette-Guérin (BCG), the only approved TB vaccine, is effective in infants, but its efficacy in adolescents and adults is limited. Here, we investigated the immune responses elicited by BCG administered via intravenous (IV) or intrader…
Méndez-Samperio P
…ous disease worldwide. Currently, Bacillus Calmette-Guérin (BCG) remains the only TB vaccine licensed for human use. This TB vaccine is effective in protecting children against severe military TB but offers variable protective efficacy in adults. Therefore, new vaccines against T…
S.H. Choi, Jiyun Park, Jung Joo Hong, Sung Jae Shin, Ju Mi Lee
The Bacillus Calmette-Guérin (BCG) vaccine, the only licensed vaccine against tuberculosis (TB), has played a crucial role in mitigating severe manifestations of the disease, particularly in children. However, its effectiveness against pulmonary TB in adults remains variable, lar…
Melkie ST, Arias L, Farroni C, Jankovic Makek M, Goletti D, et al.
…incomplete protection conferred by bacille Calmette-Guérin (BCG) vaccination against adult pulmonary TB, efforts to discover novel TB vaccines are ongoing. Efficacy studies from advanced TB vaccines designed to stimulate cell-mediated immunity failed to show protection, suggestin…
Zhuang L, Ye Z, Li L, Yang L, Gong W
…cause of mortality worldwide. Currently, the only available vaccine for TB prevention is Bacillus Calmette-Guérin (BCG). However, BCG demonstrates limited efficacy, particularly in adults. Efforts to develop effective TB vaccines have been ongoing for nearly a century. In this re…
Peter Kim, Soumya Swaminathan
…ew drugs in the clinical development pipeline, multiple new vaccine candidates, an array of new diagnostics and multiple clinical trials characterizing the efficacy and effectiveness of these new tools. For chemoprophylaxis and treatment, several new regimens have proven successf…
Wang Y, Sun Y, Zheng Y, Yang Y, He L, et al.
…uses of human death in the world. Bacillus Calmette-Guérin (BCG) provides limited protection in adolescents and adults. To explore the factors reducing efficacy of BCG vaccine, we assess the impacts of interleukin (IL)-10 and alarmins S100A8/A9 on T-cell memory. We found that BCG…
James M. Trauer, Andrew Kawai, Anna K. Coussens, Manjula Datta, Bridget M Williams, et al.
Abstract Background The variable efficacy observed in studies of BCG vaccination is incompletely explained by currently accepted hypotheses, such as latitudinal gradient in non-tuberculous mycobacteria exposure. We investigated heterogeneity in BCG vaccination in the context of p…